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INTRODUCTION
Diabetes mellitus in cats in almost 85% 
of cases resembles human type II diabetes. 
Hyperglycemia is usually the result of a low 
secretion or inadequate response to endogenous 
insulin. Insulin treatment in “normal” diabetic 
felines requires <1 IU/kg/administration, 
offering an adequate blood glucose control. If the 
initial cause of insulin deϐiciency is treated and 
exogenous insulin administration manages to hold 
a tight blood glucose control, hyperglycemia might 
resolve and thus so insulin requirement could 
seize. Requirement of doses of insulin higher 
than 1.5 IU/kg/administration or frequent dose 
ϐluctuations, should drive clinicians to evaluate 
for insulin resistance (IR) and pathologies which 
could cause an inadequate response to treatment. 
Insulin resistance is deϐined as reduced sensitivity 
to insulin, with little or no response in blood 
glucose lowering effect. Inadequate response 
to insulin is caused by low availability of insulin 
receptors (pre-receptor defect), incapacity of 
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Abstract
Hypersomathotropism is an important feline endocrinopathy, induced by a pituitary growth hormone 
secreting adenoma. Up until present, most of the diagnosed acromegalic cats were diagnosed previously with 
insulin dependent diabetes mellitus. Hypersomathotropism needs imperative exclusion when dealing with 
poor blood glucose control and insulin resistance. The present paper describes hypersomathotropism diagnosis 
protocol in two insulin resistant diabetic felines. 
Two diabetic domestic short hair cats presenting marked insulin resistance and poor blood glucose control 
were evaluated. Diagnosis protocol included anamnesis, physical evaluation and general and speciϐic biochemistry 
analysis. Diagnosis conϐirmation was obtained on contrast enhanced intracranial MRI and morphopathological 
examination.
Both cases displayed marked insulin resistance with 1.5 IU/kg/administration in the male cat (10.5 
IU/administration) and 2.4 I.U./kg/administration in the female cat (12 I.U./administration). On physical 
examination have been observed a slight inferior prognathia on the female cat, clubbed paws on the male cat, 
broad facial features and obesity (female: 5kg; male: 7 kg). Repeated blood glucose curves conϐirmed persistent 
hyperglycaemia >450 mg/dl (61-124 mg/dl) with different doses of insulin. Speciϐic biochemistry revealed an 
increased concentration of insulin like growth factor–1 determination >1000 ng/ml (208 – 443 ng/ml), above 
the cut-off for hypersomathotropism diagnosis. Contrast enhanced MRI revealed an enlarged pituitary gland 
conϐirming hypersomathotropism. Haematoxylin eosin examination of the pituitary tissue revealed acidophilic 
cells consistent with growth hormone producing cells. 
Systemic manifestations are masked by diabetes mellitus clinical signs leading to a high error degree in 
diagnostic establishment and administration of highly dangerous doses of insulin. With accurate diagnosis, case 
management and speciϐic treatment can be applied accordingly and in the favor of patient quality of life.
Keywords: acromegaly, insulin-like-growth factor-1, insulin resistance, pituitary adenoma, feline growth 
hormone. 
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insulin to bind to receptors (receptor defect), 
and/or incapacity of signal transduction 
after the binding of insulin to the receptor 
(postreceptor defect) (Scott-Moncrieff, 2010). 
The most important conditions demonstrated to 
cause insulin resistance are obesity, exogenous 
progestagens and glucocorticoid, pancreatitis, 
bacterial infections, renal and heart disease and 
neoplasia (Scott-Moncrieff, 2010). Underlying 
endocrinopathies such as hypersomathotropism, 
hyperadrenocorticism and hyperthyroidism 
evolve with high concentrations of insulin 
antagonist hormones which in turn will lead to 
an overproduction of insulin by the pancreas, 
to the exhaustion and shutdown of β-cells 
(Behrend and Kemppainen, 1997; Middleton and 
Watson, 1985; Peterson, 2007; Zini et al., 2010). 
Hypersomatotropism in cats, as in humans, is 
caused by a functional somatotrophic adenoma 
developed on growth hormone (GH) producing 
cells of the pars distalis in the anterior pituitary 
gland (Niessen, 2010; Rijnberk et al., 2003; 
Starkey et al., 2004). Insulin resistance and 
diabetes mellitus induced by GH and IGF-1 is the 
result of down regulation of insulin receptors 
and post-receptor defects in glucose transport 
(Niessen et al., 2007). In a healthy organism, GH 
secretion is stimulated by the Growth Hormone 
Releasing Hormone secreted in the hypothalamus 
and inhibited by somatostatin. In patients with 
tumours of GH producing cells, hormone secretion 
becomes autonomous and does not respond to the 
negative feedback. 
Acromegalic cats tend to be middle aged, 
with a median of 10 years, no apparent breed 
disposition and are 90% males (Niessen, 2010; 
Scott-Moncrieff, 2010). Hypersomathotropism 
clinical signs and are rarely observed by owners 
and clinicians, as they are usually discrete and 
develop over months or even years. Predominant 
clinical signs are of DM and most cases present 
poor blood glucose control and the requirement of 
high doses of insulin.
MATERIALS AND METHODS
Two diabetic domestic short hair cats, a 
14-year-old spayed female cat and a 7 year old 
unne utered male, were documented with marked 
insulin resistance and poor blood glucose control 
after being diagnosed with diabetes mellitus. 
Although insulin treatment was initiated longer 
than six weeks before revaluation, both cases 
still presented persistent polyuria (>50 ml/kg/
day), polydipsia (> 150 ml/kg/day), ravenous 
appetite and weight gain. Insulin dose has been 
increased gradually over six weeks in order to 
obtain an adequate blood glucose control. Both 
cases reached a high dangerous insulin dose of 
2.4 IU/kg/administration in the female cat (12 
IU/administration) and 1.5 IU/kg/administration 
in the male cat (10.5 IU/administration). 
Hypersomathotropism suspicion was based on 
the marked insulin resistance, weight gain and 
obesity (female: 5kg; male: 7 kg) in spite of poor 
blood glucose control. 
Patients were submitted to a clinical, cardiac 
and neurological revaluation. General biochemistry 
targeted: blood glucose level, liver enzymes, 
cholesterolemia, azotaemia, phosphataemia 
and urine biochemistry. Diagnosis conϐirmation 
was based on IGF-1, a speciϐic parameter for 
hyperadrenocorticism, and intracranial contrast 
enhanced MRI. Contrast enhanced intracranial 
MRI was performed under general anaesthesia, 
with a 1.5 Toshiba Vantage Titan, with a slice 
thickness of 3 mm. Pre and post contrast images 
were acquired in T1 and T2 in dorsal, sagittal and 
transverse planes. Contrast enhancement images 
were obtained by intravenous administration of 
gadobenate dimeglumine 0.1mmol/kg.
RESULTS AND DISCUSSION
The prevalence of feline acromegaly is 
not yet accurately known. However it could 
be the decreased awareness on the pathology 
and predominant diabetes mellitus clinical 
contri bu ting to the decreased prevalence of 
acromegaly. Diabetes mellitus is in a lot of cases 
the ϐirst pathology to be discovered and only 
later on, after insulin treatment failure, leading 
to hypersomathotropism suspicion (Feldman and 
Nelson, 2000; Meij et al., 2010). Acromegalic cats 
tend to be middle aged, with a median of 10 years, 
no apparent breed disposition and are 90% males 
(Niessen, 2010; Scott-Moncrieff, 2010). Physical 
examination often reveals: inferior prognatia, 
widened interdental spaces, respiratory stridor 
in 53 % of cases (Niessen, 2010), clubbed paws 
and weight gain (Niessen, 2010; Scott-Moncrieff, 
2010). Physical examination often reveals: 
inferior prognatia, widened interdental spaces, 
respiratory stridor in 53 % of cases (Niessen, 
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Blood results revealed hyperglycaemia, in-
creased alkaline phosphatasis, hypercholesterol-
emia, hyperkalaemia, modera tely increased 
hepatic transaminases and hyperpro teinemia. 
Urinalyses revealed marked glycosuria (>1081.08 
mg/dl) with a normal speciϐic gravity (1.020 – 
1.040) and the urine culture was negative. Speciϐic 
biochemistry revealed an increased concentration 
of insulin like growth factor–1 determination 
above the 1000 ng/ml (208 – 443 ng/ml) cut-off 
for hypersomathotropism diagnosis. 
Most acromegalic cats reported in literature 
up until now, were also were previously diag nosed 
with insulin dependent diabetes mellitus, which 
sets a differentiation from human hypersoma-
thotropism. Cats displaying IR are usually pre-
sented with persistent characteristic signs of 
diabetes mellitus, such as polyuria, polydipsia 
and polyphagia and weight gain. Increasing 
weight despite poor blood glucose control should 
be one of the factors indicating an underlying 
IR inducing endocrinopathy. A high percentage 
of diabetic hypersomathotropic cats displayed 
poorly controlled blood glucose and required 
highly dangerous doses of insulin (Dunning et 
al., 2009; Feldman and Nelson, 2000; Niessen, 
2010; Slingerland et al., 2008). Severe episodes 
of hypoglycemia are at risk, as GH has a pulsatile 
episodic secretion, leaving ϐluctuating gaps in the 
IR, when insulin could have a normal hypoglycemic 
effect. Insulin resistance can be conϐirmed if a high 
level of fructosamine >500mg/dl and persistent 
hyperglycemia on blood glucose curve are detected 
(Scott-Moncrieff, 2010). 
2010), clubbed paws and weight gain (Niessen, 
2010; Scott-Moncrieff, 2010). Physical evaluation 
in the present cases was characteristic for 
hypersomathotropism. A slight inferior prognathia 
(Fig. 1) on the female cat, clubbed paws (Fig. 2) on 
the male cat and broad facial features on both cats 
have been observed, all features representative for 
acromegaly (Niessen et al., 2007). Overgrowth of 
soft, skeletal and cartilage tissue and organomegaly 
are caused by the anabolic effect of not only GH, but 
also insulin like growth factor – 1 (IGF-1), which 
is produced mainly by the liver, under the direct 
inϐluence of high concentrations of GH (Niessen, 
2010; Rijnberk et al., 2003; Starkey et al., 2004). 
Acromegaly is characterized by slow, progressive, 
somatic disϐigurement, involving mainly the face, 
extremities and internal organs (Chanson et al., 
2009). GH and IGF-1 are involved not only in the 
proliferation of normal cells, but also neoplasic 
cells (Marek et al., 2001). Elevated concentrations 
of GH and IGF-1 lead to increased cell turnover and 
high risk of malignant transformation (Juul, 2003). 
Different forms of cancer as lymphosarcoma, 
adenocarcinoma (Norman and Mooney, 2000) 
or osteosarcoma (Abraham et al., 2002) have 
been observed in acromegalic cats. On cardiac 
auscultation, normal frequency, without murmurs 
and synchronic pulse was present on both femoral 
arteries were registered. Cats did not display 
any signs of astazia, ataxia, nistagmus, seizures 
or circling. The only neurological signs observed 
on the female case were bilateral mydriasis, 
diminished pupillary light reϐlex and aggressive 
behaviour. 
ROSCA et al
Fig. 1. Slight inferior prognatia and widened 
interdental spaces in the female cat;
Fig. 2. Clubbed paws observed 
in the acromegalic male cat;
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Conϐirmation of acromegaly includes levels 
of IGF-1, speciϐic feline GH determinations and 
intracranial imaging by contrast enhanced 
MRI (Niessen, 2010). Even with a reduced 
availability speciϐic feline GH can be determined 
in cats (Niessen et al., 2007). However GH single 
determination cannot be reliable for diagnosis, 
due to its episodic pulsatile secretion, short half-
life and inϐluence of numerous variables on serum 
levels. A higher reliability is owned by IGF-1, as it 
is secreted in a non-pulsatile fashion (Niessen et 
al., 2007; Scott-Moncrieff, 2010; Slingerland et al., 
2008), reϐlects the average 24 hour GH activity 
(Starkey et al., 2004) and has a parallel increase 
with GH (Chanson et al., 2009). IGF-1 has a highly 
conserved structure across different species and 
does not require speciϐic feline tests, making radio 
immune and ELISA assays designed for diagnosis 
of acromegaly in humans, adequate for cats (Berg 
et al., 2007; Feldman and Nelson, 2000; Niessen, 
2010; Rosca et al., 2014; Starkey et al., 2004). 
Finally, if GH and/or IGF-1 register elevated 
levels, diagnosis is conϐirmed by intracranial 
imaging of the pituitary by CT or MRI (Niessen et 
al., 2007). 
Contrast enhanced MRI revealed an enlarged 
pituitary gland conϐirming hypersomathotropism 
diagnosis (Fig. 3). The pituitary gland was descri-
bed as a nonhomogeneous mass in T1 images, 
with multiple well demarked lacunar areas of 
hypointense content and hyperintense rims. On 
the T2 examination same mixed predominant 
hypointense signal and hyperintense rims were 
observed, with one large hypointense lacuna and 
ventral hyperintense foci. Sagittal images revealed 
a nonhomogeneous highly intense rostral rim (Fig. 
3). Pituitary measurement results (Wallack et al., 
2003) indicated a height of 0.8 cm, width of 0.7 
cm, length of 0.7 cm and a volume of 0.2051 cm3. 
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Tab. 1. Blood general and speciϐic biochemistry for hypersomathotropism diagnosis
Analyte Female cat Male cat Reference range
Glucose 412 480 61-124 mg/dl
Cholesterol 176 299 71-161 mg/dl
Alkaline Phosph. 37 92 12-65 UI/L
Urea nitrogen 57 21 15-31 mg/dl
Phosphate 7.9 7.3 4-7.3 mg/dl
ALAT 31.4 46 8.3-53 UI/L
ASAT 46 68 9.2-40 UI/L
Potassium 6 5.2 3.8-5.3 mEq/l
IGF-1 1600 1000 208 – 443 ng/ml
Fig. 3. MRI Postcontrast T1 sagittal section - 
nonhomogeneous highly intense rostral rim of the 
pituitary gland;
Fig. 4. MRI Precontrast T2 sagittal section – 
Hyperintense aspect of the olfactory bulbs;
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An eventual suprasellar extension of the pituitary 
could not be demonstrated but the mass effect 
that caused the deviation of third ventricle and 
lateral ventricle asymmetry may be suggestive 
for a hypothalamic extension. Olfactory bulbs 
revealed bilateral liquid ϐilled cavitary areas, 
with grey aspect in T1 and FLAIR and white in 
T2 images, characteristic for cerebral spinal ϐluid. 
This was suggestive for an increased volume of 
ventricular cavities in the olfactory bulbs (Fig. 4), 
later conϐirmed on post-mortem examination. In 
this case the MR images revealed a pituitary gland 
with a volume of 0.2051 cm3, being considerably 
higher than in normal cats. The pituitary gland of 
adult cats with no pituitary diseases was proved to 
have a mean length of 0.54 cm (± 0.06 cm), mean 
width of 0.50 cm (± 0.08 cm), mean height 0.34 
cm (± 0.05 cm) and a mean volume of 0.05cm3 (± 
0.05cm3) with no signiϐicant correlation between 
the volume and the age or weight of the cat (Wallack 
et al., 2003). The pituitary gland was described 
as a nonhomogeneous mass with multiple well 
demarked lacunar areas of hypointense content 
and hyperintense rims. Sagittal images revealed 
nonhomogeneous highly intense rostral rims, 
which was previously reported in other studies 
and was suspected to be a consequence of fatty 
inϐiltration caused by chronic inϐlammation or 
compression (Posch et al., 2011; Wallack et al., 
2003).
Beside the ϐindings that accord with previous 
studies described in literature, in this case MR 
images indicated increased volume of olfactory 
bulbs cavities, which was also conϐirmed on the 
post-mortem examination and is the ϐirst report 
of this kind. No obstruction or compression was 
revealed between lateral ventricles and olfactory 
bulbs cavities, but this must be evaluated with 
reserve considering the small diameter of binding 
channels.
After conϐirming the diagnosis of acromegaly, 
the owner of the female had decided for euthanasia 
and agreed for necropsy. Tissue samples from the 
pituitary gland, liver, adrenal glands, kidney and the 
left submandibular gland that appeared enlarged 
were collected for histology. Haematoxylin eosin 
staining of the pituitary tissue revealed acidophilic 
cells, consistent with GH secreting cells adenomas 
(Fig. 5) with no evidence of basophilic cells cha-
rac teristic to ACTH secreting cells (Meij et al., 
2004). Markedly vacuolated islet cells in the 
pancreas, periglomerular ϐibrosis, degenerative 
and regenerative epithelial cells in the kidney and 
mild to moderate cholangiohepatitis in the liver 
tissues were also observed. Results for IGF-1 level 
showed a concentration of 1600 ng/dl (208 – 443 
ng/ml) which was suggestive for acromegaly as it 
exceeded 1000 ng/ml.
Advanced researches have been made in the 
past years on feline acromegaly. Early and accurate 
diagnosis could improve the outcome, not only for 
the main endocrinopathy but also for its secondary 
associated pathologies. Better quality of life, 
increased life expectancy and overall a better 
prognosis could be obtained. Treatment options 
for acromegaly are aimed at lowering of GH and 
ROSCA et al
Fig. 5. Pituitary gland hematoxylin eosin staining - acidophilic cells
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IGF-1, reducing tumour size and include medical 
treatment, radiotherapy protocols, surgical hypo-
physec tomy, and cryohypophysectomy (Blois and 
Holmberg, 2008; Brearley et al., 2006; Kaser-
Hotz et al., 2002; Meij et al., 2010). Although 
radiotherapy and surgical approach are considered 
curative for hypersomathotropism, these methods 
are readily chosen as they are invasive, require 
repeated sedation and imply high costs. Post 
surgical treatment requires lifelong hormonal 
replacement. Research are being made on the 
medical treatment of acromegaly, an important 
compound being pasireotide (SOM 23), a drug 
used for human Cushing’s disease treatment. In a 
study performed in 2013 by Niessen et al. results 
revel that pasireotide is able to rapidly decrease 
GH and IGF-1 concentrations in feline acromegaly. 
A clinical trial with long-acting release form of 
pasireotide is still in progress in order to establish 
long-term effects and potential for IR and DM 
remission acromegalic cats (Niessen et al., 2013). 
Acromegalic cats have a life expectancy that varies 
between 4 to 42 months. Cause of death is in most 
cases consequence of severe congestive heart 
failure, renal failure or progressive neurological 
signs caused by the expanding pituitary tumours 
(Abraham et al., 2002; Feldman and Nelson, 2000).
CONCLUSION
Insulin resistance in cats can be induced by a 
various number of conditions and endocrinopathies. 
Error rate in the establishment of diagnosis is high 
and is dependable on the clinicians experience 
and knowledge of all pathologies which could lead 
to a poor blood glucose control. Insulin resistance 
recognition and further evaluation for underlying 
pathologies is essential for a favourable disease 
outcome and a good quality of life for the patient. 
Hypersomathotropism has an insidious evolution, 
with discrete clinical signs, often marked by 
diabetes mellitus concurrent evolution. Systemic 
manifestations are dominated by diabetes mellitus 
clinical signs leading to a high error degree to, a 
delayed accurate diagnosis and administration 
of highly dangerous amounts of insulin. Con seq-
uently, so is the speciϐic treatment for hyperso-
matotropism. Early diagnosis could offer along 
with the most suitable therapeutic measures a 
better prognostic. Insulin administration should 
not exceed certain dose unless all underlying 
pathologies have been excluded. Also cats recei-
ving high doses of insulin should be under a 
constant care and monitoring in order to prevent 
life threatening hypoglycaemic episodes.
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